C4 Therapeutics, Inc. (CCCC) stock
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/302% below fair value
$2.48+0.04 (+1.64%)
Close on Nov 20, 2026Market cap $305.10MP/E –Yield –
C4 Therapeutics gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
No gross profit figures for C4 Therapeutics
C4 Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?